 ObsEva SA OBSV SIX:OBSN, a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today reported that there will be an online publication of two abstracts in Obstetrics and Gynecology The Green Journal, the official journal of the American College of Obstetricians and Gynecologists, on Thursday 23rd April at 5pm ET. The abstracts, titled Quality of Life Results After 52 Weeks of Treatment with Linzagolix for Endometriosis-Associated Pain and Linzagolix for Endometriosis-Associated Pain: Lipid Changes After 52 Weeks of Treatment are based on 52-week data from the EDELWEISS trial, a Phase 2b randomized, double-blind, placebo-controlled, dose-ranging trial conducted in the US and Europe to assess the safety and tolerability of a range of daily oral linzagolix doses 50 to 200 mg in women with moderate to severe endometriosis-associated pain. 